309 related articles for article (PubMed ID: 34905030)
1. Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke.
Kent DM; Saver JL; Kasner SE; Nelson J; Carroll JD; Chatellier G; Derumeaux G; Furlan AJ; Herrmann HC; Jüni P; Kim JS; Koethe B; Lee PH; Lefebvre B; Mattle HP; Meier B; Reisman M; Smalling RW; Soendergaard L; Song JK; Mas JL; Thaler DE
JAMA; 2021 Dec; 326(22):2277-2286. PubMed ID: 34905030
[TBL] [Abstract][Full Text] [Related]
2. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
[TBL] [Abstract][Full Text] [Related]
3. Association of Atrial Septal Aneurysm and Shunt Size With Stroke Recurrence and Benefit From Patent Foramen Ovale Closure.
Mas JL; Saver JL; Kasner SE; Nelson J; Carroll JD; Chatellier G; Derumeaux G; Furlan AJ; Herrmann HC; Jüni P; Kim JS; Koethe B; Lee PH; Lefebvre B; Mattle HP; Meier B; Reisman M; Smalling RW; Sondergaard L; Song JK; Thaler DE; Kent DM
JAMA Neurol; 2022 Nov; 79(11):1175-1179. PubMed ID: 36215079
[TBL] [Abstract][Full Text] [Related]
4. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
Pickett CA; Villines TC; Ferguson MA; Hulten EA
Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
[TBL] [Abstract][Full Text] [Related]
5. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
6. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials.
Kent DM; Saver JL; Ruthazer R; Furlan AJ; Reisman M; Carroll JD; Smalling RW; Jüni P; Mattle HP; Meier B; Thaler DE
Stroke; 2020 Oct; 51(10):3119-3123. PubMed ID: 32921262
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
[TBL] [Abstract][Full Text] [Related]
8. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
[TBL] [Abstract][Full Text] [Related]
9. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
10. A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke.
Kasner SE; Sondergaard L; Nakum M; Gomez Montero M; Hashim M; Landaas EJ
J Med Econ; 2024; 27(1):337-343. PubMed ID: 38373018
[TBL] [Abstract][Full Text] [Related]
11. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
[TBL] [Abstract][Full Text] [Related]
12. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
[TBL] [Abstract][Full Text] [Related]
13. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Michel P
Int J Cardiol; 2013 Oct; 169(2):101-5. PubMed ID: 24041984
[TBL] [Abstract][Full Text] [Related]
14. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
[TBL] [Abstract][Full Text] [Related]
15. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
[TBL] [Abstract][Full Text] [Related]
17. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
[TBL] [Abstract][Full Text] [Related]
18. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
19. Patent foramen ovale closure versus medical therapy after cryptogenic stroke: An updated meta-analysis of all randomized clinical trials.
Kheiri B; Abdalla A; Osman M; Ahmed S; Hassan M; Bachuwa G
Cardiol J; 2019; 26(1):47-55. PubMed ID: 29512097
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
